Latest Breaking News On - Cancer facts - Page 25 : comparemela.com

RenovoRx (RNXT) Announces New Positive Interim Phase III Data Demonstrating RenovoGem Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

RenovoRx (RNXT) Announces New Positive Interim Phase III Data Demonstrating RenovoGem Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMichaelj pishvaianShaun bagaiJack perkinsStrategic communicationsRenovorx incExchange commissionWorld congress on gastrointestinal cancerTiger pac data monitoring committeeSecurities exchangeAmerican cancer society facts figuresGastrointestinal cancerJohns hopkins medicinePrincipal investigatorR pac data monitoring committeeTrans arterial micro perfusion

RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesShaun bagaiMichaelj pishvaianJack perkinsRenovorx incSecurities exchangeTiger pac data monitoring committeeStrategic communicationsAmerican cancer society facts figuresExchange commissionCompany nasdaqWorld congress on gastrointestinal cancerSix month overall survival benefitLocally advanced pancreaticGastrointestinal cancerJohns hopkins medicine

AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE REFRACTORY PROSTATE CANCER (mCRPC), STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION UNTIL 2042 Paris, 2.

France generalUnited statesEuropean patent conventionAmerican cancer societyEuropean patent officeEuropean patentCancer factsEuronext paris

AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)

AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesEuropean patent officeEuropean patent conventionAmerican cancer societyEuropean patentIssue supplementCancer factsEuronext paris

Testicular Cancer - Risk Factors - Symptoms - Diagnosis - Staging - Treatment

A person with testicular cancer may have a testicle that is three times its original size. The most cited risk factor is undescended testes.

United statesNew zealandReeja tharuFactors to considerDiagnosing finger nailGerm cell tumorsCancer factsTesticular cancerTesticular cancer awareness campaigns comparedBreast cancer awareness month accordingInternet search volumesGoogle trendsPatients with testicular carcinoma is dependentTestosterone levelSystematic review